For full details on each session, please view the event guide.

8:00 am

Registration & Welcome Coffee

Humanised Mouse Models

9:15 am Chair’s Opening Remarks

9:30 am Targeting of Tumor-Specific HLA Ligands with Bispecific T Cell-Engaging Receptor (TCER™) Molecules

  • Frank Schwöbel Associate Director- Preclinical Pharmacology and Toxicology, Immatics


• XPRESIDENT® to exploit the repertoire of tumor-associated antigens
• Introduction into TCER™, Immatics’ TCR bispecific molecules
• TCER™ in vivo data

10:00 am Patient-Derived Experimental Models for Translational Cancer Research


• Overcoming drug development challenges
• Organoids: Demonstrating clinical relevance in 3D in vitro modeling
• Mouse Clinical Trials (MCTs) more closely represent the human clinical trial situation

10:30 am

Speed Networking & Morning Break

Syngeneic & PDX Models

11:30 am The Clinical IAP Antagonist ASTX660 Drives Anti-Tumor Immunity in T Cell Lymphoma

  • Nicola Ferrari Research Associate- Translational R&D, Astex Pharmaceuticals


• ASTX660 is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP, which has demonstrated preliminary evidence of single agent clinical activity in T cell lymphoma (TCL) patients
• To investigate the mechanism of action behind the single agent activity seen in the clinic we have used a comprehensive translational approach
via the integration of in vitro coculture systems and in vivo preclinical models with human patient data from our clinical trial
• We describe a novel role for ASTX660 as an immunomodulatory molecule, capable acting on both the innate and adaptive immune system, which could be exploited to remodel the tumor immune microenvironment

12:00 pm Considerations for the correct implementation of PDX models in Immuno-Oncology


• What are Patient Derived Xenograft (PDX) models?
• Traditional versus humanised PDX models
• Generation of PDX models for Immuno-Oncology?
• Applications of PDX models in Immuno-Oncology

12:30 pm SubQperior: A Superior Syngeneic Model System to Subcutaneous Tumour Models

  • Holger Weber Head of In Vivo Pharmacology, Reaction Biology Europe GmbH


• Introducing the next generation of tumour models for immuno-oncology efficacy studies overcoming common problems experienced with subcutaneous tumour implantation

12:45 pm

Networking Lunch

1:45 pm Panel Discussion: Limitations of Humanised & PDX Models

  • Frank Schwöbel Associate Director- Preclinical Pharmacology and Toxicology, Immatics
  • Nicola Ferrari Research Associate- Translational R&D, Astex Pharmaceuticals
  • Christiane Amendt Global Head - Translational In Vivo Pharmacology, Translational Innovation Platform Oncology, Merck KGaA


• How can we push these borders to include more supporting immune cells, dendritic cells, NK-cells?
• Increasing longevity; CD34 humanised hyper immune-deficient mice can increase available study lengths but also increase the cost. Is there a middle ground?
• Gaining data on persistence of cellular therapies without requiring additional mice

Next Generation Preclinical Models for IO

2:30 pm The Role of Biomarkers in the Transition from Preclinical Models to Clinical Trials in Immuno-Oncology



  • Overview of different biomarkers and their functions
  • Preclinical immuno-oncology models and biomarkers
  • Brief discussion of biomarkers in immuno-oncology clinical trials

2:45 pm Targeting Kras: Pros and Cons of In Vitro Tools Versus Mouse Models

  • Chiara Ambrogio Assistant Professor MBC (Molecular Biotechnology Centre), University of Turin


• Can genetic models discriminate between tumour initiating and tumour maintaining effects of KRAS?
• Can we improve the identification of biomarkers for better treatment options?
• Can genetic models be used to predict the toxicity of new KRAS-specific drugs?

3:15 pm The Next Generation of In Vivo Model for Oncology and Immuno-Oncology Drug Candidates


• INOVOTION’s technology opens new perspectives of in vivo screening in oncology and immuno-oncology
• Chicken embryo model has several advantages over traditional in vivo models for the discovery of cancer drugs
• Chicken embryo model fills the gap between in vitro and vivo evaluations, that’s why it’s possible to predict mouse data from chicken embryo results

3:45 pm

Afternoon Tea Break & Poster Session

4:30 pm Immune Checkpoints; Humanised Preclinical Models for Biologics’ Efficacy & MoA

  • Kader Thiam Vice President of Transgenic Technologies, genOway


• Exploring how model design impacts the physiological relevance and the predictability of preclinical outcomes

5:00 pm What do We Need for Next Gen Model to Enhance Predictability & Targeting?


• Next gen mice model vs CRISPR-based model
• How can we identify cancer resistance during preclinical stage?
• Utilizing gene editing to avoid building cell lines

5:30 pm End of Day 1

5:45 pm Poster & Drinks Reception

For full details on each session, please view the event guide.